| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
|---|---|
| maladie des jambes | Ill-defined disease seen among rice-growers in Louisiana. (05 Mar 2000) |
| peste des petits ruminants virus | A highly contagious systemic disease of sheep and goats in West Africa, caused by a morbillivirus called peste des petits ruminants virus. It is characterised by fever, anorexia, a necrotic stomatitis with gingivitis, diarrhoea and can often cause a severe, often fatal enteritis and pneumonia. (20 Sep 2002) |
| complement 5a, des-arginine | Complement 5a with the carboxy-terminal arginine removed. The arginine is rapidly cleaved from the c5a fragment during complement activation by carboxypeptidase b present in normal human serum. C5a des-arg shows complete loss of spasmogenic activity though it retains some chemotactic ability. (12 Dec 1998) |
| Corvisart des Marets | Baron Jean N., French clinician, 1755-1821. See: Corvisart's facies. (05 Mar 2000) |
| DES | <drug> A synthetic oestrogen (originally prescribed to prevent miscarriage) that caused malformations of the reproductive organs in some who were exposed to the drug during foetal development. (09 Oct 1997) |
| des- | <chemistry, prefix> A prefix indicating absence of some component of the principal part of the name; largely replaced by de-(e.g., deoxyribonucleic acid, dehydro-) but retained where "de" could be taken for d or d, as part of "desmo" (e.g., desmosterol), and in such terms as desoxycortone. (05 Mar 2000) |
| des(121-124)-ribonuclease | <enzyme> Deriv of ribonuclease EC 3.1.4.22 Registry number: EC 3.1.4.- Synonym: des(121-124)-rnase (26 Jun 1999) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |